Russia and Belarus are being frozen out of international science, with universities and research institutions across Europe suspending joint research projects and calling a halt to the formation of any new collaborations, following the invasion of Ukraine. Initial sanctions announced by European governments called for the severing of direct institution-to-institution links only, with many universities counseling individual researchers to maintain personal relations with Russian peers.
As the conflict in Ukraine intensifies following the Russian invasion, hundreds of clinical trials could be in jeopardy amid the chaos and destruction of war, with pharma giant Merck & Co. Inc. saying it is putting recruitment for dozens of studies on hold.
Though the Ukraine war has had an impact on the availability of medical devices and diagnostics, a number of companies based in the U.S. and Europe have announced measures to ensure their products will reach the war-torn nation. Device companies are donating millions to nongovernmental organizations for humanitarian assistance, while the Advanced Medical Technology Association (Advamed) said its member companies are tracking the situation and are eager to pitch in with desperately needed supplies and medical equipment.
The indirect impact of the Russian invasion of Ukraine on the life sciences sector continues to grow, as the West responds with more and more sanctions against Russia. In one of the latest moves, the European Commission announced March 4 that it is suspending cooperation with Russian entities in research, science and innovation.
Europe’s pharmaceutical industry has warned the conflict in Ukraine is disrupting supplies of medicines and clinical trials, while pledging free medicines to the humanitarian effort to those caught in or fleeing from the Russian invasion. A representative of the European Federation of Pharmaceutical Industries and Associations, which has an affiliate in Ukraine, told BioWorld that the disruption has left pharma industry staff in that country taking to emergency shelters.
Russia’s Ministry of Health is looking to extend its role on the global stage. Over the next few months, the ministry, along with other regulatory agencies in Russia, said it plans to start the accreditation process of coming into compliance with World Health Organization (WHO) standards.
Russia’s Ministry of Health is looking to extend its role on the global stage. Over the next few months, the ministry, along with other regulatory agencies in Russia, said it plans to start the accreditation process of coming into compliance with World Health Organization (WHO) standards.
The Russian Ministry of Health issued the 14th version of its guidelines on preventing, diagnosing and treating COVID-19 infections. Released Dec. 28, the latest version includes information about the Omicron variant and provides updates on new therapies, including two new oral drugs: Pfizer Inc.’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) and Merck & Co. Inc.-Ridgeback Biotherapeutics Inc.’s siRNA drug molnupiravir, which will be marketed in Russia as Mir-19.
The Russian Federation is making progress in building its drug supply system and increasing access to medicines and medical devices. In a Dec. 7 update on the progress being made, Minister of Health Mikhail Murashko highlighted the work of the Circle of Kindness fund, efforts to ensure the availability of vaccines and other drugs throughout the federation, and the launch of a labeling system to promote the timely identification of uncertified and counterfeit drugs.
PARIS – A Russian research consortium has discovered that coating magnetic nanoparticles with a non-magnetic silica shell significantly decreased the viability of cancer cells in a low frequency alternating magnetic field. This discovery may augur new therapeutic prospects for nanotechnology combined with medical imaging.